- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07443436
Immunomodulerende behandeling van interstitiële longziekte geassocieerd met surfactant-gerelateerde genvarianten (TIPS)
Scientific justification : Variants in surfactant-related genes (SRG) explain approximately 6% of familial pulmonary fibrosis (FPF).
The pathophysiology is unknown and seems to involve endoplasmic reticulum stress in type 2 alveolar epithelial cells.
Variable improvement in the prognosis of childhood and adult interstitial lung disease (ILD) associated with a variant of a SRG, initially reported to be lethal within months of diagnosis, has been observed since the consensual use of prednisone, azithromycin and hydroxychloroquine targeting endoplasmic reticulum stress, without demonstration of the efficacy of any of these treatments alone or in combination.
The investigators hypothesize that a treatment combining prednisone, azithromycin and hydroxychloroquine is safe and could improve the prognosis of adult patients with ILD associated with SRG variant.
Main objective and primary endpoint : Main objective:
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene.
Primary endpoint:
Difference in forced vital capacity decline between the 2 groups at one year.
Secondary objectives and endpoints : Secondary objectives:
- tolerance of the triple therapy,
- correlation between the respiratory, radiological and clinical functional response,
- quality of life of the patients,
- overall survival, transplant-free survival, exacerbation free-survival, hospitalization-free survival
Secondary endpoints:
- Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at one year after randomization)
- Thoracic CT scan and PFT at 6 months and one year after randomization
- Quality of life questionnaire (EORTC QLQ-C30, v3.0) at 3 months, 6 months, 9 months and one year after randomization,
- Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization.
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care
Category : Category 2
Population of study participants: Patients aged over 18 years with ILD and SRG variant
Number of participants included : 30
Design of the study : Multicenter, randomized, controlled, two-arm, parallel, open-label superiority study comparing triple immunomodulatory therapy (prednisone, azithromycin, and hydroxychloroquine) to standard of care.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Annabelle METOIS
- Telefoonnummer: 0140257939
- E-mail: annabelle/metois@aphp.fr
Studie Contact Back-up
- Naam: BORIE Raphaël
- E-mail: raphael.borie@aphp.fr
Studie Locaties
-
-
-
Bron, Frankrijk, 69500
- Pneumologie Louis Pradel
-
Contact:
- COTTIN Vincent
- E-mail: vincent.cottin@chu-lyon.fr
-
Lille, Frankrijk, 59037
- Pneumologie Institu Coeur Poumon
-
Contact:
- WEMEAU Lidwine
- E-mail: lidwibne.wemeau@chru-lille.fr
-
Rennes, Frankrijk, 35033
- Pneumologie Pontchaillou
-
Contact:
- JOUNEAU Stéphane
- E-mail: stephane.jouneau@chu-rennes.fr
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥ 18 years and <80 years
- Carrier of a variant classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in SFTPA1, SFTPA2, SFTPC, NKX2-1, SFTPB or two variants classified as pathogenic or probably pathogenic or considered as eligible by the genetic multidisciplinary discussion in ABCA3 or SFTPB
- ILD whatever the pattern corresponding to a volume > 10% of the total lung on a CT scan of less than 2 years
Exclusion Criteria:
- Contraindication to azithromycin and hydroxychloroquine and prednisone (details in section 6.2)
- Pregnancy and breastfeeding
- Female of childbearing potential* not willing to use reliable contraception from inclusion and during 22 months
- Desire to have a child within 22 months
- Enrolment to another interventional study (clinical trial on medicinal product, medical device and interventional research involving human participants not concerning health product)
- Subject deprived of their liberty or subject that may have insufficient power, intelligence, education, resources, strength, or other needed attributes to protect their own interests; or unable to explicitly give consent.
- No affiliation to any health insurance system
- Refusal to participate to the study
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Prednisone 10 mg/day -Hydroxychloroquine 400 mg/day - Azithromycin 250mg*3
The experimental treatment will be the combination of:
|
Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no Route of administration: oral route Duration of treatment: 12 months Market authorization: yes Use in their market authorization indication: no |
|
Actieve vergelijker: Standard of care
Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study. |
Standard of care: any symptomatic treatment to interstitial lung disease. No other experimental or off-label treatment (such as ivacaftor) will be allowed during the study. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Difference in forced vital capacity decline between the 2 groups at one year.
Tijdsspanne: 12 Months
|
Evaluate the efficacy of triple immunomodulatory therapy (prednisone, azithromycin and hydroxychloroquine) for 12 months in patients with ILD associated with a variant of a surfactant-related gene. |
12 Months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
tolerance of the triple therapy
Tijdsspanne: 12 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) (at 3, 6, 9, 12 months after randomization) (only HCQ or AZI patients) and ophthalmological (at 6 months and 12 months after randomization) |
12 months
|
|
correlation between the respiratory, radiological and clinical functional response,
Tijdsspanne: 12 months
|
Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at one year after randomization |
12 months
|
|
Quality of life of the patients
Tijdsspanne: 12 months
|
Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at one year after randomization, |
12 months
|
|
tolerance of the triple therapy
Tijdsspanne: 6 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 6, months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization) |
6 months
|
|
tolerance of the triple therapy
Tijdsspanne: 3 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) and ophthalmological (at one year after randomization) |
3 months
|
|
correlation between the respiratory, radiological and clinical functional response,
Tijdsspanne: 6 months
|
Thoracic CT scan (progression criteria [99]) and PFT (Pulmonary function tests) at 6 months after randomization |
6 months
|
|
Quality of life of the patients
Tijdsspanne: 9 months
|
Quality of life questionnaire (SF-36,scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 : a validated patient-reported questionnaire for assessing quality of life in cancer patients.) at 9 months after randomization, |
9 months
|
|
Quality of life of the patients
Tijdsspanne: 6 months
|
Quality of life questionnaire (SF-36 scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients. ) at 6 months after randomization, |
6 months
|
|
Quality of life of the patients
Tijdsspanne: 3 months
|
Quality of life questionnaire (SF-36, scale from 0 to 100, where 0 represents the poorest health and 100 represents the best possible health) (EORTC QLQ-C30, v3.0 :a validated patient-reported questionnaire for assessing quality of life in cancer patients ) at 3 months after randomization, |
3 months
|
|
Overall survival
Tijdsspanne: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Transplant-free survival
Tijdsspanne: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Exacerbation free-survival
Tijdsspanne: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
Hospitalization-free survival
Tijdsspanne: 12 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 12 months after randomization |
12 months
|
|
tolerance of the triple therapy
Tijdsspanne: 9 months
|
Clinical and biological tolerance (occurrence of an adverse effect during treatment), |
9 months
|
|
tolerance of the triple therapy
Tijdsspanne: 12 months
|
ECG (including QTc prolongation) at 12 months after randomization (only HCQ or AZI patients) |
12 months
|
|
tolerance of the triple therapy
Tijdsspanne: 12 months
|
Ophthalmological (at one year after randomization) |
12 months
|
|
tolerance of the triple therapy
Tijdsspanne: 9 months
|
ECG (including QTc prolongation) at , 9 months after randomization (only HCQ or AZI patients) |
9 months
|
|
tolerance of the triple therapy
Tijdsspanne: 6 months
|
ECG (including QTc prolongation) at 6 months after randomization (only HCQ or AZI patients) |
6 months
|
|
tolerance of the triple therapy
Tijdsspanne: 3 months
|
ECG (including QTc prolongation) at 3 months after randomization (only HCQ or AZI patients) |
3 months
|
|
Overall survival
Tijdsspanne: 9 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 9 months after randomization |
9 months
|
|
Overall survival
Tijdsspanne: 6 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 6 months after randomization |
6 months
|
|
Overall survival
Tijdsspanne: 3 months
|
Collection of vital status, lung transplantation, hospitalization for pulmonary and non-pulmonary causes and episodes of exacerbation at each visit until the end of follow-up 3 months after randomization |
3 months
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Ziekten van de luchtwegen
- Longziekten
- Longziekten, interstitieel
- Organische chemicaliën
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Polycyclische verbindingen
- Zwangerschap
- Zwangere
- Steroïden
- Verbindingen met gefuseerde ring
- Macrolides
- Lactonen
- Zwangerschap
- Chinolines
- Aminoquinolines
- Erytromycine
- Polyketiden
- Chloroquine
- Prednison
- Hydroxychloroquine
- Azitromycine
Andere studie-ID-nummers
- APHP251230
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .